GNC: Grain Giant - From Trough to Triumph
Deep value agricultural infrastructure play trading at $8.62 vs $17.80 fair value. 60% ECA market share, 5.2% yield, processing expansion catalyst.
View noteDeep value agricultural infrastructure play trading at $8.62 vs $17.80 fair value. 60% ECA market share, 5.2% yield, processing expansion catalyst.
View noteG8 Education trades at 8.9x EV/EBITDA versus peers at 12.8x. Fair value $1.14 versus current $0.83 implies 37% upside with 94% NQS quality rating.
View noteEvolution Mining analysis reveals fair value $2.49 with deteriorating outlook. Strong operations face commodity normalisation and margin compression over forecast period.
View noteHigh-quality digital automotive marketplace leader trading at fair value. $38.76 fair value vs $37.53 current price implies 3.3% upside with defensive growth characteristics.
View noteBTI trades at 21% discount to $1.64 NAV despite 33% portfolio IRR. Fair value $1.61 implies 33% upside with 6% franked yield.
View noteBell Financial Group trades at $1.23 versus $2.34 fair value, offering 90% upside through platform transformation with $96.8m net cash providing downside protection.
View noteAurizon trades at $3.27 vs fair value $5.39, offering 65% upside through monopoly infrastructure resilience and critical minerals diversification despite coal transition headwinds.
View noteAdrad Holdings: Fair value $0.95 vs current $0.66 (44% upside). HOLD rating. Industrial manufacturer with 4.9% market share, 10.8% EBITDA margins compressing, ROIC 6.4% destroying value. Data centre exposure offset by Asian competition and execution risks.
View noteTemple & Webster fair value $7.76, EBITDA margins expanding 3.1% to 4.5% peak, 70% Amazon expansion risk, 12.8% ROIC, growth-oriented investors
View noteBUY rating with $2.19 fair value vs $1.94 current price. 24.8% ROIC, debt-free balance sheet, 21-year safety record. Infrastructure supercycle exposure.
View noteClinical-stage RNA therapeutics with validated platform technology trading at $1.26 versus $14.41 fair value, offering 1,044% upside potential for growth investors.
View noteAustralia's #4 health insurer trades 15% above A$6.48 fair value. Strong 15.1% ROIC offset by transformation execution risks. Quality franchise, challenging outlook.
View note